Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
KPLH1130
Cat. No.:
0225LY-0744
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
KPLH1130 is a specialized pyruvate dehydrogenase kinase (PDK) inhibitor that improves glucose tolerance in mice on high-fat diets while also reducing proinflammatory responses and blocking macrophage polarization.
Synonym:
906669-07-6; 3-(2,4-dihydroxyphenyl)-4-(4-methylphenyl)-1H-1,2,4-triazol-5-one; 5-(2,4-dihydroxyphenyl)-4-(4-methylphenyl)-2H-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 5-(2,4-dihydroxyphenyl)-2,4-dihydro-4-(4-methylphenyl)
CAS No.:
906669-07-6
Compound CID:
135487465
Formula:
C15H13N3O3
Formula Weight:
283.28
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
KPLH1130 can be used in oncology research to study the role of PDK inhibition in suppressing tumor cell proliferation.
Library Information
Target:
PDH; PDK
Receptor:
PDH; PDK
Pathways:
PI3K/Akt/mTOR signaling; Metabolism
Plate Number:
AOCL-10
Plate Location:
e11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
83.33 mg/mL; 294.16 mM
